This document provides an overview of hepatic and pancreatic tumors. It discusses the clinical anatomy and physiology of the liver and pancreas. It describes different types of benign hepatic tumors like hemangiomas, adenomas, and focal nodular hyperplasia. For malignant hepatic tumors, it discusses hepatocellular carcinoma and cholangiocarcinoma. It covers the epidemiology, investigations, and management options for these tumors. For the pancreas, it discusses anatomy, physiology, tumor types including neuroendocrine tumors, and the management of pancreatic tumors through surgery or palliation.
2. OBJECTIVES
1. Clinical anatomy of liver
2. Physiology of liver
3. Different types of benign hepatic tumors
4. Management of different types of benign
hepatic tumors
5. Types of malignant hepatic tumors
6. Epidemiology of malignant hepatic tumors
7. Management of different malignant hepatic
tumors
3. OBJECTIVES (CONTD…)
9. Clinical anatomy of pancreas
10. Physiology of pancreas
11. Different types of pancreatic tumors
12. Management of different types of pancreatic
tumors
4. 1. CLINICAL ANATOMY OF LIVER
Largest organ in the body
Situated in the RHC
Weight = 1.5 kg in a 70 kg man
Covered by a capsule & visceral peritoneum
except ‘bare area’ on its posterior surface
Two lobes, right & left; right lobe = 3/4th, left
lobe = smaller
6. LIGAMENTS & PERITONEAL REFLECTIONS
Left & right triangular ligaments
Falciform ligament (remnant of umbilical
vein)
Lesser omentum between stomach & liver,
contains the hilar structures
Porta hepatis = hilum of the liver
Hepatic artery, portal vein & bile duct are
present within the free edge of the lesser
omentum
10. SEGMENTAL ANATOMY OF LIVER
Eight segments (described by Couinaud)
Each segment is a functional unit with a
branch of hepatic artery, portal vein & bile
duct
14. LIVER HEMANGIOMAS
Having abnormal plexus of veins
Often multiple, may be giant
Usually found incidentally (incidentaloma)
Usually diagnosed by US
CT scan shows characteristic slow contrast
enhancement due to small vessel uptake
Percutaneous biopsy should be avoided
Rarely need surgery
16. HEPATIC ADENOMA
Mostly occur in women of child-bearing age
Associated with sex hormones (OC pills)
CT or MRI shows a well-circumscribed
vascular solid tumor
Difficult to differentiate from HCC
Biopsy may be necessary
May bleed and have malignant potential
Resection is the treatment of choice
18. FOCAL NODULAR HYPERPLASIA (FNH)
It is a focal overgrowth of functioning liver tissue
supported by fibrous stroma
Usually middle-aged women
US helps to diagnose but may not be able to
discriminate
Contrast CT/MRI may show central scarring &
well-vascularized lesion
FNH contains both hepatocytes & Kupffer cells
A sulphur colloid liver scan may be useful, since
Kupffer cells take up the colloid
Does not have malignant potential
If diagnosis is confirm, no treatment is required
20. 4. MANAGEMENT OF BENIGN HEPATIC TUMORS
Liver hemangiomas = Rarely require surgery
Hepatic adenoma = Resection is the
treatment of choice
FNH = No treatment is required
22. HEPATOCELLULAR CARCINOMA (HCC)
Primary liver cancer
Associated with chronic liver disease (CLD),
due to HBV & HCV
Many patients with CLD are now screened
for HCC by serial USS of liver or serum α-FP
Surgical treatment options include:
1. Resection of the tumor
2. Liver transplant
24. Choice of surgical option from the above two
depends upon:
a. Stage of the underlying liver disease
b. Site & size of the tumor
c. Availability of organ transplantation
d. Management of the immunosuppressed
patient
25. STAGING & CLINICAL ASSESSMENT OF HCC
General assessment of patient for fitness of
surgery
Severity of underlying liver disease (by CTP
classification or MELD score)
Size, number and site of the tumor
26. Points 1 point
each
2 points
each
3 points
each
Bilirubin
(µmol/L)
<34 34-50 >50
Albumin (g/L) >35 22-35 <25
Ascites None Easily
controlled
Poorly
controlled
Encephalopath
y
None Grade I-II Grade III-IV
INR <1.7 1.7-2.2 >2.2
CHILD-TURCOTTE-PUGH (CTP)
CLASSIFICATION OF HEPATOCELLULAR
FUNCTION IN CIRRHOSIS
CTP A = 5-6 Points; CTP B = 7-9 Points; CTP C = 10-15
Points
27. MODEL FOR END-STAGE LIVER DISEASE (MELD)
SCORE
It is a scoring system for assessing the severity
of chronic liver disease
It was initially developed to predict death within
three months of surgery in patients who had
undergone a transjugular intrahepatic
portosystemic shunt (TIPS) procedure and was
subsequently found to be useful in determining
prognosis and prioritizing for receipt of a liver
transplant
This score is now used by the United Network
for Organ Sharing (UNOS) and
Eurotransplant for prioritizing allocation of liver
transplants instead of the older CTP score
28. MODEL FOR END-STAGE LIVER DISEASE (MELD)
SCORE
MELD = 3.78×ln[serum bilirubin (mg/dL)] +
11.2×ln[INR] + 9.57×ln[serum creatinine
(mg/dL)] + 6.43×aetiology(0: cholestatic or
alcoholic, 1- otherwise)
In interpreting the MELD Score in hospitalized
patients, the 3 month mortality is:
1. 40 or more — 71.3% mortality
2. 30–39 — 52.6% mortality
3. 20–29 — 19.6% mortality
4. 10–19 — 6.0% mortality
5. <9 — 1.9% mortality
29. USS
CXR/CT
Bone scan
Contrast CT/MRI
WHVP (Wedged hepatic venous pressure);
suggests portal hypertension, poor outcome
after liver resection in cirrhotic patients
Indocyanine green (ICG) clearance test: for
hepatic flow & function
Patients with CTP class A and high ICG
clearance are suitable for major liver
resection
30. CHOLANGIOCARCINOMA
Bile duct cancers typically present with
painless obstructive jaundice
PSC (Primary Sclerosing Cholangitis) is the
cause
Slow growing tumors
Klastskin tumors: arise at the confluence of
right & left hepatic ducts, eventually invading
the liver parenchyma
31. INVESTIGATIONS FOR CHOLANGIOCARCINOMA
LFTs: Obstructive jaundice
Tumor marker: CA 19-9 may be elevated
USS
MDR-CT: Multidetector row computed
tomography
MRI/MRCP
ERCP
PTC
PET
32. 6. EPIDEMIOLOGY OF MALIGNANT HEPATIC
TUMORS
Sixth most common cancer worldwide
5.7% incidence over all cancers
Developing countries = 82%, third most
common cancer in men after lung & stomach
HBV & HCV infections account 75% cases of
primary liver cancers
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036307/
33. 7. MANAGEMENT OF MALIGNANT HEPATIC
TUMORS
For HCC:
Surgical resection with 1 to 2-cm safety
margin
Liver transplantation
Non-surgical therapy for advanced disease:
a. Transarterial embolization (TAE)
b. Transarterial chemoembolization (TACE)
c. Percutaneous ethanol ablation (PEA)
d. Radiofrequency ablation (RFA)
34. 8. CLINICAL ANATOMY OF PANCREAS
Exocrine & endocrine pancreas
Head, body, tail, uncinate process
Main pancreatic duct (Wirsung)
Accessory pancreatic duct (Santorini)
Islets of Langerhans
a) B-cells (65-80%) : Insulin
b) A-cells (15-20%) : Glucagon
c) D-cells (3-10) : Somatostatin
d) PP-cells (1%) : Pancreatic polypeptide
35. 9. PHYSIOLOGY OF PANCREAS
In response to meal, secretin from duodenal
mucosa: stimulates pancreas to secrete
digestive enzymes in an alkaline (pH 8.4)
bicarbonate-rich fluid
Cholecystokinin-panceozymin (CCK-PZ)
Vagal stimulation: secretomotor
36. 10. DIFFERENT TYPES OF PANCREATIC TUMORS
Chronic pancreatitis may be the main cause
Carcinoma of pancreas: 85% are ductal
adenocarcinomas
Serous and mucinous cystadenomas
including intraductal papillary mucinous
neoplasms (IPMNs)
Lymphangiomas, dermoid cysts
38. 11. MANAGEMENT OF DIFFERENT TYPES OF
PANCREATIC TUMORS
1/3rd of pancreatic tumors arise in its head
Ampullary carcinoma
Causing characteristic painless obstructive
jaundice
Pruritus, dark urine, pale stools, steatorrhea
If no jaundice, symptoms are vague e.g.
discomfort, anorexia, weight loss
39. INVESTIGATIONS
CBC, UCE, FBS, RBS, LFTs
USS
Contrast CT/MRI
ERCP
±Transduodenal or Transgastric FNA or
Trucut biopsy performed under EUS
guidance
Percutaneous transperitoneal biopsy should
be avoided
40. PREOPERATIVE PREPARATION
In a patient with obstructive jaundice:
a. Well hydration to prevent hepatorenal shut
down
b. Vitamin K injections
c. Prophylactic antibiotics
41. TREATMENT
Curative surgery if possible ± chemotherapy
of 5-FU, radiotherapy is not effective
1. Pylorus-preserving panceatoduodenectomy
(PPPD)
2. Whipple procedure
3. Total pancreatectomy if the disease is
multifocal
4. Distal pancreatectomy with splenectomy +
local lymphadenectomy: tumors of body/tail
43. CONTRAINDICATIONS TO SURGICAL RESECTION
Presence of:
1. Hepatic or peritoneal metastases
2. Lymph node metastases distant from the
pancreatic head
3. Encasement of the SMA, hepatic or coeliac
artery
44. Palliation of pancreatic cancer
A.Relieve jaundice & treat biliary sepsis
Surgical biliary bypass
Stent placed at ERCP or PTC
B.Improve gastric emptying
Surgical gastroenterostomy
Duodenal stent
C.Pain relief
Stepwise escalation of analgesia
Coeliac plexus block
Transthoracic splanchnicectomy
D.Symptom relief & quality of life
Encourage normal activities
Enzyme replacement for steatorrhea
Treat diabetes
E.Consider chemotherapy
45. References: Bailey & Love’s Short Practice
of Surgery; 26th Edition; Chapters 52, 65, 68